Benzene, 1-methoxy-3-methyl-5-(1-methylethoxy)- | 1369857-79-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Benzene, 1-methoxy-3-methyl-5-(1-methylethoxy)-
• 英文别名: 1-methoxy-3-methyl-5-propan-2-yloxybenzene
• CAS: 1369857-79-3
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.24
• InChiKey: CFFZRTFUJSNMMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS DE 2-PYRIDAZIN-3(2H)-ONE À SUBSTITUTION 2-ARYLE ET 2-HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE FGFR TYROSINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017070708A1

  公开（公告）日：2017-04-27

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

  本文提供了一般式I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中X、R1、R2、R3、环A和z的含义如规范中所述，这些化合物是FGFR1、FGFR2、FGFR3和/或FGFR4的抑制剂，可用于治疗和预防可以用FGFR抑制剂治疗的疾病，包括由FGFR1、FGFR2、FGFR3和/或FGFR4介导的疾病或障碍。
• CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3191445B1

  公开（公告）日：2019-06-12
• 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES
  申请人：Array BioPharma, Inc.

  公开号：US20170260168A1

  公开（公告）日：2017-09-14

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R 1 , R 2 , R 3 , Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
• US7238714B2
  申请人：——

  公开号：US7238714B2

  公开（公告）日：2007-07-03